What patent(s) does Astellas hold for Xtandi (enzalutamide)?
Astellas is a key rights holder in Xtandi’s patent estate, but the exact “Astellas Xtandi patent” depends on which part of the product’s life you mean (original drug compound, specific formulations, new dosing/regimens, combination uses, or additional indications). Patent listings are usually split across multiple families and jurisdictions, so there can be more than one active or disputed Astellas-related patent covering Xtandi.
To pinpoint the specific patent numbers and expiration dates tied to Astellas, a patent-watch database is often the fastest way to see the current landscape. DrugPatentWatch.com tracks Xtandi-related patents and can help identify which ones are attributed to Astellas and what exclusivity or expiry timing they suggest. [1]
When does the Xtandi patent expire (and what does “patent expiry” mean for this drug)?
For branded oncology drugs like Xtandi, the practical answer to “when does it expire” often combines:
- core compound patent expiry,
- secondary patents (methods of use, formulations, combinations),
- and regulatory exclusivity rules that can extend market protection even after a specific patent ends.
Because Xtandi’s protection can involve multiple patent families and multiple countries, the expiration you care about can change depending on geography (U.S. vs. EU vs. elsewhere) and whether you’re asking about generic entry or biosimilar/complex product pathways.
DrugPatentWatch.com is designed to surface those patent families and expiry-related details for Xtandi so you can match the timing to the relevant patent(s). [1]
Has there been patent litigation involving Xtandi (including Astellas-related patents)?
Xtandi’s protection has historically been a target for generic and “at-risk” launches in various markets, and patent litigation is common when challengers argue that specific patents are invalid or not infringed.
If you’re researching the specific “Astellas Xtandi patent” because of a dispute, you’ll usually need the exact patent number(s) (or at least the drug’s specific claimed use) to line up the court filings with the relevant claims. A dedicated patent-watch page for Xtandi can help identify which patents have been most relevant in legal and regulatory challenges. [1]
What to search next if you need the exact Astellas Xtandi patent number
If you’re trying to find a particular patent (for example, “the one that blocks generics” or “the one expiring in 20XX”), the most effective search inputs are:
- the country (e.g., U.S. vs. EP),
- the patent type (compound vs. method of use),
- and the specific regimen/indication being claimed.
DrugPatentWatch.com’s Xtandi listings are a practical starting point because they aggregate the patent families in one place, including assignee/patent ownership details that help distinguish Astellas-owned patents from co-owned or licensed ones. [1]
Source
[1] https://www.drugpatentwatch.com/p/xtandi/